NasdaqGS:MRNABiotechs
Assessing Moderna (MRNA) Valuation After Recent Share Price Momentum And Mixed Long Term Returns
Recent performance snapshot and why Moderna is on watch
With no single headline event driving attention today, Moderna (MRNA) is drawing interest after a mixed performance, including a 1.8% gain over the past month and a stronger move over the past 3 months.
For context, the stock closed at US$54.26, with a market value near US$21.0b. This compares with a track record that includes a 75.8% year to date total return and about 115.4% over the past year, while the 3 year and 5 year total returns...